

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Immunex Corporation	03/17/2009

RECEIVING PARTY DATA

Name:	Celldex Therapeutics, Inc.
Street Address:	222 Cameron Drive, Suite 400
City:	Phillipsburg
State/Country:	NEW JERSEY
Postal Code:	08865

PROPERTY NUMBERS Total: 21

Property Type	Number
Patent Number:	5554512
Patent Number:	6630143
Patent Number:	5843423
Patent Number:	6919206
Patent Number:	6190655
Patent Number:	6632424
Patent Number:	7041282
Patent Number:	7045128
Patent Number:	7294331
Patent Number:	7361330
Patent Number:	7150992
Patent Number:	6017527
Patent Number:	6497876
Patent Number:	7067118
Patent Number:	6291661

CH \$840.00 5554512

501048722

**PATENT
 REEL: 023679 FRAME: 0893**

Patent Number:	5565321
Patent Number:	6613320
Patent Number:	6106832
Patent Number:	5674492
Application Number:	11448708
Application Number:	12187575

CORRESPONDENCE DATA

Fax Number: (617)742-4214
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 617-227-7400
Email: cjb@lahive.com
Correspondent Name: LAHIVE & COCKFIELD, LLP
Address Line 1: One Post Office Square
Address Line 4: Boston, MASSACHUSETTS 02109-2127

ATTORNEY DOCKET NUMBER: CDJ-000

NAME OF SUBMITTER: Jill Gorny Sloper, Esq.

Total Attachments: 12
source=CDJ_Assignment_1#page1.tif
source=CDJ_Assignment_1#page2.tif
source=CDJ_Assignment_1#page3.tif
source=CDJ_Assignment_1#page4.tif
source=CDJ_Assignment_1#page5.tif
source=CDJ_Assignment_1#page6.tif
source=CDJ_Assignment_1#page7.tif
source=CDJ_Assignment_1#page8.tif
source=CDJ_Assignment_1#page9.tif
source=CDJ_Assignment_1#page10.tif
source=CDJ_Assignment_1#page11.tif
source=CDJ_Assignment_1#page12.tif

ASSIGNMENT

WHEREAS IMMUNEX CORPORATION, (hereinafter, "ASSIGNOR"), a wholly-owned subsidiary of Amgen Inc. and a corporation organized and existing under the laws of the State of Washington, and having a place of business at 51 University Street, Seattle, Washington 98101, is the assignee of interest in inventions set forth in U.S. and foreign patents and U.S. and foreign patent applications and any continuation, continuation-in-part, divisional, substitute, reissues, re-examinations, and extensions thereof (collectively, "Patent Documents"), listed in Appendix A hereto; and

WHEREAS Celldex Therapeutics, Inc., (hereinafter, "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a place of business at 222 Cameron Drive, Suite 400, Phillipsburg, NJ 08865, is desirous of acquiring all interest in and to said inventions and to the Patent Documents listed in Appendix A.

NOW, THEREFORE, be it known to all whom it may concern:

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does hereby irrevocably sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, all of Assignor's right, title and interest, as of the Effective Date, in, to and under the issued patents set forth on Appendix A and any reissues, reexaminations, and extensions thereof, and the patent applications set forth on Appendix A and all patents of the United States which may be granted thereon, and all divisions, renewals, continuations, and substitute applications thereof, and all patents worldwide that may be granted thereon, and all reissues, reexaminations, and extensions thereof, together with the right to file such applications and the right to claim for the same the priority rights derived from such patent application under the patent laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, to be held and enjoyed by ASSIGNEE for its own use and enjoyment, and for the use and enjoyment of its successors and assigns, to the end of the term or terms for which such letters patent may be granted or reissued, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment and sale had not been made, each of the foregoing including, to the extent applicable, the right to seek damages and/or injunctive relief in the event of infringement of any such issued patent, with the right to sue for and receive the same for Assignee's own account and use, solely to the extent such infringement occurs from and after the Effective Date, and, to the extent set forth above, for the use and on behalf of its successors and assigns.

ASSIGNOR HEREBY authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this Assignment, and hereby grants the attorney of record the power to insert on this Assignment any further identification of the

issued patents and the patent applications set forth on Appendix A that is necessary under the rules of the United States Patent and Trademark Office, and the patent office of any country or countries foreign to the United States, for recordation of this Assignment, and agrees, without further consideration, at Assignee's expense, to execute and deliver such other documents that Assignee, its successors and/or assigns may reasonably request that are necessary under the rules of the United States Patent and Trademark Office, and the patent office of any country or countries foreign to the United States, for recordation of this Assignment; provided that Assignee shall be solely responsible for performing all activities in connection with recordation of this Assignment with the United States Patent and Trademark Office, and the patent office of any country or countries foreign to the United States.

ASSIGNOR HEREBY covenants and agrees that it has the full right to convey the interest herein assigned, and ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith.

[Signatures Appear on the Following Page]

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representative effective as of the date shown below.

This 17 day of March, 2009.

IMMUNEX CORPORATION



By: Stuart L. Watt
Name: Stuart L. Watt
Title: Vice President, Law and Intellectual Property Officer

STATE OF WASHINGTON

COUNTY OF []

On [], before me, _____, personally appeared _____, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Signature _____ (Seal)

My Commission Expires:

[Signatures Continue on Next Page]

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of Ventura

On March 17, 2009 before me, Karen E. Podgorny, Notary Public


Date

Here Insert Name and Title of the Officer

personally appeared Stuart L. Watt

Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Karen E. Podgorny

Signature of Notary Public

Place Notary Seal Above

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

- Individual
- Corporate Officer — Title(s): _____
- Partner — Limited General
- Attorney in Fact
- Trustee
- Guardian or Conservator
- Other: _____

RIGHT THUMBPRINT OF SIGNER
Top of thumb here

Signer Is Representing: _____

Signer's Name: _____

- Individual
- Corporate Officer — Title(s): _____
- Partner — Limited General
- Attorney in Fact
- Trustee
- Guardian or Conservator
- Other: _____

RIGHT THUMBPRINT OF SIGNER
Top of thumb here

Signer Is Representing: _____

IN WITNESS WHEREOF, Assignee has caused this Assignment to be to be executed by its duly authorized representative effective as of the date shown below.

This 20 day of MARCH, 2009.

CELLEX THERAPEUTICS, INC.

By: Anthony S. Marucci
Name: ANTHONY S. MARUCCI
Title: PRESIDENT & CEO

STATE OF NEW JERSEY

COUNTY OF [Hudson]

On [3-20-09], before me, Kathy Reamer, personally appeared Anthony Marucci, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Signature Kathy D. Reamer (Seal)

My Commission Expires:

KATHY D. REAMER
NOTARY PUBLIC OF NEW JERSEY
MY COMMISSION EXPIRES
FEBRUARY 7, 2012

Status	Internal Title	Filing No.	Filing Date	Pub. No.	Pub. Date	Grant No.	Grant Date	Amgen Patent Family Ref.	Country
Grant	Ligands for flt3 Receptors	08/243,545	11 May 1994			5,554,512	10 Sep 1996	2813-US-CIP5	United States of America
Grant	Antibodies Against flt3 Ligand	08/569,692	24 Jun 1996			6,630,143	07 Oct 2003	2813-US-CIP6	United States of America
Grant	Methods of Stimulating Hematopoietic Cells with flt3 Ligand	08/993,962	18 Dec 1997			5,843,423	01 Dec 1998	2813-US-CIN7	United States of America
Grant	Medium Containing flt3 Ligand for Culturing Hematopoietic Cells	08/994,468	19 Dec 1997	US20030148516	07 Aug 2003	6,919,206	19 Jul 2005	2813-US-CPA	United States of America
Grant	Methods of Using flt3 Ligand for Exogenous Gene Transfer	09/160,841	25 Sep 1998			6,190,655	20 Feb 2001	2813-US-CPA2	United States of America
Grant	Human flt3 Ligands	08/444,626	19 May 1995			6,632,424	14 Oct 2003	2813-US-DIV	United States of America
Grant	Ligands for flt3 Receptors	09/983,806	25 Dec 2001	US20020107365	09 Aug 2002	7,041,282	09 May 2006	2813-US-DIV5	United States of America

Amgen Contract No. 200903766
 BOS111 12346693.2
 BOS111 12356964.2

A-2

Assigned AMG949/950 Patent Rights

Status	Internal Title	Filing No.	Filing Date	Pub. No.	Pub. Date	Grant No.	Grant Date	Amgen Patent Family Ref.	Country
Grant	Antibodies Against Flt3 Ligand	10/095,449	13 Mar 2002	US20020150004	31 Oct 2002	7,045,128	16 May 2006	2813-US-DIV6	United States of America
Grant	Methods of Using flt3-Ligand in Hematopoietic Cell Transplantation	10/314,035	05 Dec 2002	US20030157069	21 Aug 2003	7,294,331	13 Nov 2007	2813-US-DIV7	United States of America
Publication of Appln	Methods of Using flt3-Ligand in the Treatment of Cancer	11/448,708	08 Jun 2006	US20070207164	06 Sep 2007			2813-US-DIV8	United States of America

Amgen Contract No. 200903766
 BOS111 12346693.2
 BOS111 12356964.2

A-3

Assigned AMG949/950 Patent Rights

Status	Internal Title	Filing No.	Filing Date	Pub. No.	Pub. Date	Grant No.	Grant Date	Amgen Patent Family Ref.	Country
Grant	Methods of Using flt3-Ligand in the Treatment of Fibrosarcoma	10/241,927	11 Sep 2002	US20030113341	19 Jun 2003	7,361,330	22 Apr 2008	2836-US-CNT	United States of America
Filing	Methods of Using Flt3-Ligand for Augmenting an Immune Response for the Treatment of Cancer	12/187,575	07 Aug 2008					2836-US-CNT3	United States of America
								2836-1K-CP	
Grant	Methods of Preparing Dendritic Cells with flt3-Ligand and Antigen	09/699,923	30 Oct 2000			7,150,992	19 Dec 2006	2836-US-DIV2	United States of America

Amgen Contract No. 200903766
 BOS111 12346693.2
 BOS111 12356964.2

A-5

Assigned AMG949/950 Patent Rights

Status	Internal Title	Filing No.	Filing Date	Pub. No.	Pub. Date	Grant No.	Grant Date	Amgen Patent Family Ref.	Country
Grant	Activated Dendritic Cells and Methods for Their Activation	08/763,995	12 Dec 1996			6,017,527	25 Jan 2000	2845-US-CNT	United States of America
Grant	Method of Stimulating an Immune Response with Activated Dendritic Cells	09/430,448	29 Oct 1999			6,497,876	24 Dec 2002	2845-US-CNT2	United States of America
Grant	Methods of Using Mutant f1c3-Ligand Polypeptides to Induce Cellular Expansion	09/904,536	16 Jul 2001	US20020111475	15 Aug 2002	7,067,118	27 Jun 2006	2857-US-DIV	United States of America

Amgen Contract No. 200903766
 BOS111 12346693.2
 BOS111 12356964.2

A-6

Assigned AMG949/950 Patent Rights

Status	Internal Title	Filing No.	Filing Date	Pub. No.	Pub. Date	Grant No.	Grant Date	Amgen Patent Family Ref.	Country
Grant	rit3-L Mutants and Methods of Use	09/109,100	02 Jul 1998			6,291,661	18 Sep 2001	2857-US-NP	United States of America
Grant	Detection of Mutations in a CD40 Ligand Gene	08/164,422	21 Jan 1994			5,568,321	15 Oct 1996	2810-US-CIP	United States of America
Grant	Defective CD4+ Cells that Express Active CD40-L	09/546,993	10 Apr 2000			6,613,320	02 Sep 2003	2810-US-CNT	United States of America
Grant	Treatment Of Individuals Exhibiting Defective CD40L	08/589,771	22 Jan 1996			6,106,832	22 Aug 2000	2810-US-CPA	United States of America

Amgen Contract No. 200903766
 BOS111 12346693.2
 BOS111 12356964.2

Status	Internal Title	Filing No.	Filing Date	Pub. No.	Pub. Date	Grant No.	Grant Date	Amgen Patent Family Ref.	Country
Grant	Method of Preventing or Treating Disease Characterized by Neoplastic Cells Expressing CD40	08/360,923	21 Dec 1994			5,674,492	07 Oct 1997	2818-US-CIP	United States of America

Amgen Contract No. 200903766
 BOS111 12346693.2
 BOS111 12356964.2

A-9

Assigned AMG949/950 Patent Rights